Literature DB >> 1457582

Treatment of neutropenia in Felty's syndrome with granulocyte-macrophage colony-stimulating factor--hematological response accompanied by pulmonary complications with lethal outcome.

A R Gari-Bai1, C Rochlitz, M Riewald, J Oertel, D Huhn.   

Abstract

We report on a 67-year-old man with Felty's syndrome (FS) complicated by recurrent pneumonia and an infected wound, which was not healing in spite of maximal antibiotic and local therapy. Encouraged by previous experience, we treated him with granulocyte-macrophage colony-stimulating factor (GM-CSF). His total leukocyte count rose, but the patient's pneumonia deteriorated. In addition, a previously known chronic obstructive lung disease (COLD) was exacerbated acutely. These complications finally led to his death. Postmortem examination revealed widespread pneumonia with invasive aspergillosis and a peripheral adenocarcinoma in his left lung.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1457582     DOI: 10.1007/bf01703951

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  31 in total

Review 1.  Colony-stimulating factors and host defense.

Authors:  R H Weisbart; J C Gasson; D W Golde
Journal:  Ann Intern Med       Date:  1989-02-15       Impact factor: 25.391

2.  Treatment with granulocyte-macrophage colony stimulating factor and the adult respiratory distress syndrome.

Authors:  G Verhoef; M Boogaerts
Journal:  Am J Hematol       Date:  1991-04       Impact factor: 10.047

3.  GM-CSF in the treatment of Felty syndrome.

Authors:  G Joseph; D H Neustadt; J Hamm; M Kellihan; T Hadley
Journal:  Am J Hematol       Date:  1991-05       Impact factor: 10.047

4.  Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever.

Authors:  B Biesma; E G de Vries; P H Willemse; W J Sluiter; P E Postmus; P C Limburg; A C Stern; E Vellenga
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

5.  Improvement of pneumonia and arthritis in Felty's syndrome by treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF).

Authors:  A S Lübbe; N Schwella; H Riess; D Huhn
Journal:  Blut       Date:  1990-12

6.  Production of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor.

Authors:  S D Sisson; C A Dinarello
Journal:  Blood       Date:  1988-10       Impact factor: 22.113

7.  A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.

Authors:  E G de Vries; B Biesma; P H Willemse; N H Mulder; A C Stern; J G Aalders; E Vellenga
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

8.  Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial.

Authors:  R Powles; C Smith; S Milan; J Treleaven; J Millar; T McElwain; E Gordon-Smith; S Milliken; C Tiley
Journal:  Lancet       Date:  1990-12-08       Impact factor: 79.321

9.  Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor.

Authors:  G J Lieschke; J Cebon; G Morstyn
Journal:  Blood       Date:  1989-12       Impact factor: 22.113

10.  Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.

Authors:  J A Thompson; D J Lee; P Kidd; E Rubin; J Kaufmann; E M Bonnem; A Fefer
Journal:  J Clin Oncol       Date:  1989-05       Impact factor: 44.544

View more
  1 in total

1.  G-CSF in Felty's syndrome: correction of neutropenia and effects on cytokine release.

Authors:  R Schots; L A Verbruggen; C Demanet
Journal:  Clin Rheumatol       Date:  1995-01       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.